Alzamend Neuro Inc (ALZN)

[Monksdream]

The DD board has been discussing it. They're not sure what to make of it, either.

[WiseYoda]

Its great momentum going into the weekend....makes it more likely that it will carry over to Monday. Lots eyes will be here PM Monday morning.

[TheFinalCD]

show it!!!

[TheFinalCD]

3.03 x 3.05 lookin better a/h

maybe because its a friday ah?


dunno, we shall see monday

[WiseYoda]

Indeed it is!

$ALZN

[Golden Cross]

Starting off good at least WY.... $ALZN

[WiseYoda]

Exactly what I was thinking.

[Golden Cross]

Bet we see some nice AH's and PM Monday on this puppy

[WiseYoda]

Indeed!

[TheFinalCD]

what a freakin struggle


WOW~!

[WiseYoda]

13k shares @ 2.92 looking good....time for power hour!

[Golden Cross]

132 MIlly Volume so far!

[beambe]

https://alzamend.com/

[beambe]

Alzamend Neuro Inc (ALZN)
2.88 ? 0.59 (25.76%)
Volume: 127,451,046 @11/05/21 2:10:18

[beambe]

BUY
Initiation Report November 5, 2021
Alzamend Neuro
NASDAQ: ALZN: $2.29 Target: $15.00
James Jang
Director of Research
[e-mail]
212.343.8888
From the Earth to the Brain, Lithium Puts the
Li in Life: Initiating Coverage of Alzamend
(ALZN)

Investment recommendation
Investment Highlights
• AL001 use for Alzheimer’s Disease is a way to shorten the timeline for
the other indications of depression, PTSD, and bipolar disorder where
we believe there is a better market for lithium. The FDA has programs
in place for breakthrough therapies and fast track that allow
experimental drugs to get through the approval process faster.
Alzamend has the potential to file for these programs with their AL001
drug for Alzheimer’s, which would allow for quicker data gathering that
can then be used for the other indications. Since AL001 will be the
same formulation for each indication, safety and tolerability can be
skipped for the other indications and trials can smaller and quicker
which can reduce time to approval.
• Reformulation of an approved therapy allows for easy acceptance with
safer profile. Lithium Carbonate has been an approved therapy for
many years for bipolar disorder and off-label use for depression. While
it is an approved therapy, there are still many risks associated with this
treatment; with high levels of lithium causing liver and kidney damage.
Alzamend’s new formulation helps to limit these issues while extending
the therapeutic window (reduce dosage), while maintaining a high level
of efficacy. Since Lithium is an approved therapy, we expect AL001 to
have a shorter pathway through clinical trails. This should lead to a
reduction in the time to approval, lower costs, and the potential for
quicker revenue generation.
Based on our discounted cash flow (DCF) methodology, we value ALZN at
$15 per share which is based on about a 1.0x multiple to our DCF derived
price of $14.81. Currently, we are conservatively omitting AL001 and AL002
indications for Alzheimer’s Disease from our estimates at this time. While we
believe ALZN’s differentiated approach to Alzheimer’s Disease could serve as
a major catalyst, at this time we view the AL001 and AL002 programs for
Alzheimer’s Disease as a free call option at current valuation levels. Therefore,
we initiate coverage of ALZN with a BUY rating and $15 price target.
REVENUE (000s)
EBITDA (000s)
Consumer Products - Nutraceuticals
EPS
We are initiating coverage of Alzamend Neuro (ALZN) with a BUY rating and
$15 price target. We believe ALZN could unlock a quicker pathway to
revenue generation by utilizing its patented AL001 (LiProSal) ionic cocrystal
to treat a host of psychiatric disor

[WiseYoda]

I was impatient and jumped in at 2.92. Such an amateur move but oh well. This one is moving more north.

[TheFinalCD]

i missed the dip to 2.68

grrrr

[WiseYoda]

13k @ 2.92 lets go!

[beambe]

Buy recommendation target price $ 15

[Golden Cross]

Alzamend Neuro shares soar 26% on large shareholder buy
https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/86480124/alzamend-neuro-shares-soar-26-on-large-shareholde

[TheFinalCD]

https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/86480124/alzamend-neuro-shares-soar-26-on-large-shareholde



is that a joke 100k shares @ .0004??

https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/86469970/statement-of-changes-in-beneficial-ownership-4


Stock Options (Right to Buy) $0.0004 11/3/2021 M 100000 (5) 4/29/2026

[TheFinalCD]

whats that?

[beambe]

BUY
Initiation Report November 5, 2021
Alzamend Neuro
NASDAQ: ALZN: $2.29 Target: $15.00
James Jang
Director of Research
[e-mail]
212.343.8888
From the Earth to the Brain, Lithium Puts the
Li in Life: Initiating Coverage of Alzamend
(ALZN)

Investment recommendation
Investment Highlights
• AL001 use for Alzheimer’s Disease is a way to shorten the timeline for
the other indications of depression, PTSD, and bipolar disorder where
we believe there is a better market for lithium. The FDA has programs
in place for breakthrough therapies and fast track that allow
experimental drugs to get through the approval process faster.
Alzamend has the potential to file for these programs with their AL001
drug for Alzheimer’s, which would allow for quicker data gathering that
can then be used for the other indications. Since AL001 will be the
same formulation for each indication, safety and tolerability can be
skipped for the other indications and trials can smaller and quicker
which can reduce time to approval.
• Reformulation of an approved therapy allows for easy acceptance with
safer profile. Lithium Carbonate has been an approved therapy for
many years for bipolar disorder and off-label use for depression. While
it is an approved therapy, there are still many risks associated with this
treatment; with high levels of lithium causing liver and kidney damage.
Alzamend’s new formulation helps to limit these issues while extending
the therapeutic window (reduce dosage), while maintaining a high level
of efficacy. Since Lithium is an approved therapy, we expect AL001 to
have a shorter pathway through clinical trails. This should lead to a
reduction in the time to approval, lower costs, and the potential for
quicker revenue generation.
Based on our discounted cash flow (DCF) methodology, we value ALZN at
$15 per share which is based on about a 1.0x multiple to our DCF derived
price of $14.81. Currently, we are conservatively omitting AL001 and AL002
indications for Alzheimer’s Disease from our estimates at this time. While we
believe ALZN’s differentiated approach to Alzheimer’s Disease could serve as
a major catalyst, at this time we view the AL001 and AL002 programs for
Alzheimer’s Disease as a free call option at current valuation levels. Therefore,
we initiate coverage of ALZN with a BUY rating and $15 price target.
REVENUE (000s)
EBITDA (000s)
Consumer Products - Nutraceuticals
EPS
We are initiating coverage of Alzamend Neuro (ALZN) with a BUY rating and
$15 price target. We believe ALZN could unlock a quicker pathway to
revenue generation by utilizing its patented AL001 (LiProSal) ionic cocrystal
to treat a host of psychiatric disorders.
The recommendations and opinions expressed in this research report accurately reflect the Investment Analyst’s personal, independent, and
objective views about any and all the Designated Investments and Relevant Issuers discussed herein. For important information, please see
the Import Disclosures section in the appendix of this document.


SHARE PRICE PERFORMANCE
Valuation
Cash (000)
GAAP EPS
BIOTECHNOLOGY F2021 F2022E F2023E
1Q ($0.03)A ($0.03)E
2Q ($0.02)E ($0.03)E
3Q ($0.02)E ($0.03)E
4Q ($0.02)E ($0.02)E
FY ($0.07)A ($0.10)E ($0.10)EF2021 F2022E F2023E
1Q $15,618A $8,461E
2Q $14,880E $4,938E
3Q $13,533E $13,393E
4Q $12,032E $11,614E
FY $1,929A $12,032E $11,614E -
10,000,000
20,000,000
30,000,000
40,000,000
50,000,000
60,000,000
$2.00
$4.00
$6.00
$8.00
$10.00
$12.00
$14.00
6/15/2021 7/15/2021 8/15/2021 9/15/2021 10/15/2021
Volume (RHS) Price (LHS)Comp a ny St a t ist ics
Closing Price 11/4/2021 $2.29
52-week Range $2.04 - $33.55
Market Cap (M): $198.97
Avg. Daily Volume: 2,119,516
Debt (M): 0.34
Risk Profile: High
Fiscal Year End: April

[beambe]

file:///C:/Users/BERNHA~1/AppData/Local/Temp/Univest_Securities_-_Alzamend_Neuro_Intiation_2021-1.pdf

[TheFinalCD]

102M volume on 84m o/s 44 float https://finviz.com/quote.ashx?t=ALZN


this chit has to be illegal


its freakin sad that they can manipulate, wash trade, naked short the hell out of anything they want, not much we can do about it, ecxcept shake our heads and try to make some money off the BS

[europtiger]

Thx for heads up… bought 3

[TheFinalCD]

cRAZY lEGS


ALZN

[Avidfisher]

I bought 15k shares last few days per my confidence, per these recent preliminary results. Got 5k of it today @ $2.18 average.

[PennyStockTrader2]

this is languishing bad, and you cant even write call options against it with such crappy premiums. Look even right now the 2.50 call for december is fetching like 30 cents, big-woof, not worth it. Nobody believes that the price will rise, which is just when it can. That said I picked up 1000 shares just in case it does.

[zagdad]

Ascendiant Capital Markets initiates coverage of ALZN with a buy and an initial projection of $8, Serious write up and my initial read liked what I saw. Not a paid promotion but a serious coverage per the disclosures IMHO.

It follows on the great news from the FDA yesterday on their trials.

https://ascendiant.sharefile.com/share/view/1b052a7017b340be

[PennyStockTrader2]

took advantage of the spike today to sell some shares and write some Oct 5.0 calls which should go out worthless. I would buy on pullback to maybe the 2.60 range.

[europtiger]

I buy the volume breakout 3,05 stop 2,65

[europtiger]

Bought 3,05

[Roadtojourney]

And down it goes pump and dump pos?? Imo

[PennyStockTrader2]

well here we are in the toilet of toilets. Cant even write calls on my position b/c the premiums are pathetic for the $5 calls. Best thing to do is just keep buying at these prices, wait for a spike, and write calls if the premiums are decent at that time. Actually I bought the Feb 22 2.5 calls in spirit of following Todds lead.

[Roozy]

Perhaps…..

[Roozy]

Under $3!!
Why?

[Roozy]

Patient Safety Technologies
Surgicount Med
SOLD!!
As will Alzn be eventually

[Hercules1]

This can open at $8 tomorrow.

[Hercules1]

52 week high for this stock is $33.


News today is significant.


It leaps over $10 soon.

[Roadtojourney]

This is a pos company and management junk, not going anywhere imo??

[Hercules1]

FDA approval is huge for this stock.


this is significant news:

https://finance.yahoo.com/news/alzamend-neuro-receives-fda-study-190700753.html?.tsrc=fin-srch

[peterus]

lol

[zagdad]

Yep great next step...whatever you are in at you will be better than good IMHO.

https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/85691798/alzamend-neuro-receives-fda-study-may-proceed

[Bucd]

And boom. News out. That was great buy for sure. I'm in at way too high. Stil red. Lol

[zagdad]

Probably making it one of the well below the radar gems that would be a great buy down here. The products they are working on are going to be industry leaders I hear.

[Roadtojourney]

This junk has lost almost 80% since live pos??

[make it happen]

Only phase 1/2a long way to go.

The cash on hand and burn gets me.

They only have 165 thousand cash & burning 10 times that. While losing over negative 1,000% equity.

165k cash gone in a month. Prob negative now just most current info.

[Roadtojourney]

Seems like the management is still on pinksheet mode of sell on news pos imo??

[zagdad]

News out - A must read

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/85655582/alzamend-neuro-receives-positive-results-for-al002